-
2024-516030-35-00
5
2025-04-30
Multiple myeloma
-
2024-516363-92-00
5
2025-04-08
Psychosis Associated with Alzheimer’s Disease
-
2023-509234-19-00
4
2025-03-03
Participants With Newly Diagnosed Resectable Stages II-IIIB (N2) Non-s
-
2023-509146-35-00
6
2025-01-30
Systemic Lupus Erythematosus
-
2023-510322-32-00
5
2025-01-27
patients with incurable, metastatic/recurrent head and neck squamous c
-
2023-510323-30-00
5
2025-01-24
First-line treatment of recurrent or metastatic PD-L1+ head and neck s
-
2023-508813-18-00
4
2024-12-18
Refractory Focal Onset Epilepsy
-
2024-514354-67-00
5
2024-11-01
Systemic lupus erythematosus
-
2023-504724-25-00
5
2024-10-16
Primary Myelofibrosis
-
2023-508338-33-00
5
2024-10-01
Chronic Inflammatory Demyelinating Polyneuropathy
-
2023-507064-39-00
5
2024-09-26
generalized Myasthenia Gravis
-
2023-508811-21-00
10
2024-09-25
Refractory Focal Onset Epilepsy
-
2024-513087-26-00
5
2024-09-10
Metastatic Non-small Cell Lung Cancer
-
2023-508162-15-00
5
2024-07-12
Chronic HF and comorbid impairment of kidney function who had a recent
-
2023-506308-24-00
10
2024-05-22
Recurrent or metastatic head and neck squamous cell carcinoma
-
2023-503317-29-00
5
2024-04-12
Metastatic renal cell carcinoma (mRCC)
-
2023-504031-41-00
5
2024-03-25
ER+/HER2- Early Breast Cancer
-
2023-507396-21-00
4
2023-03-16
transfusion-dependent α- or β-thalassemia or low-risk myelodysplastic
-
2024-516728-32-00
10
2021-10-29
Indolent Systemic Mastocytosis and SSM
-
2023-503435-17-00
5
2021-03-31
Juvenile psoriatic arthritis
-
2023-508922-83-00
10
2021-03-17
Advanced Non-Small Cell Lung Cancer
-
2023-509343-27-00
11
2019-10-28
C3 Glomerulopathy or idiopathic immune-complex membranoproliferative g
-
2023-503433-21-00
5
2019-10-03
Behçet’s disease is a chronic, relapsing, multisystem inflammatory dis
-
2025-521970-33-00
5
2025-12-19
Pulmonary Arterial Hypertension (PAH)